Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
Business Wire•23/10/2026•09:15 ET
0
Key Highlights
- ➤PIKTOR matched or exceeded intravenous gedatolisib in two breast cancer xenograft models
- ➤PIKTOR plus fulvestrant and palbociclib halted growth or shrank tumors in mice
- ➤PIKTOR reduced AKT activity to approximately 10% of uninhibited levels
- ➤FTH-PIK-201 topline endometrial cancer data expected by year-end 2026
- ➤FTH-PIK-101 interim breast cancer data expected in 2027
Expert Statements
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“These data strengthen our conviction that oral multi-node inhibition of the PI3K/AKT/mTOR pathway is achievable and that PIKTOR can work alongside standard of care.”
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“In HR+/HER2- advanced breast cancer, we believe PIKTOR may offer patients an all-oral option designed to address the limits of single-node inhibitors, and it could give Faeth a differentiated position relative to gedatolisib, another multi-node inhibitor which is intravenous by design.”
Anand Parikh, Chief Executive Officer of Faeth Therapeutics
“We believe we can translate this science into clinical evidence, with topline data from our Phase 2 FTH-PIK-201 trial in second-line advanced endometrial cancer by year-end 2026 and interim data from our Phase 1b/2 FTH-PIK-101 trial in breast cancer in 2027.”
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
In two preclinical breast cancer xenograft models (abstract #431P), PIKTOR inhibited tumor growth to a comparable or greater extent than intravenous gedatolisib
Get started
Create a free account to read the full story.